Cancer-Related Fatigue During Maintenance Immunotherapy for Non-Small Cell Lung Cancer

Inclusion Criteria

• * ≥ 18 years of age at the time of consent * Must be able to speak, read, and understand English * Participants diagnosed with NSCLC, and: ** Have advanced/metastatic disease who are currently receiving immunotherapy monotherapy, or ** Have locally advanced disease who are currently receiving immunotherapy monotherapy after completing thoracic radiation therapy, or ** Who underwent resection and are currently receiving immunotherapy monotherapy after completing all other perioperative treatment * Immunotherapy planned to continue for at least three months after the time of study enrollment (to ensure participant remains on IO long enough to obtain study assessments) * Have completed at least two cycles of immunotherapy * Self-reported cancer-related fatigue that impacts daily function

Exclusion Criteria

• * Participants who have received a dose of chemotherapy (including maintenance pemetrexed) within the past 3 months * Participants who have received radiation therapy within the past 3 months. ** Note: a short course of palliative radiation therapy within up to 20 Gy and up to 5 fractions is permissible. * Diagnosis of dementia. * Anemia Hgb < 10 g/dL. * Sarcopenia which is being pharmacologically treated with a prescribed appetite stimulant (e.g., megestrol). * Untreated hypothyroidism. * Symptomatic heart failure. * Oxygen dependent lung disease. * Cognitively unable to complete interviews per investigator